Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available.
BioArctic AB and its partner Eisai have submitted a new drug application in Japan for a subcutaneous formulation of Leqembi, an anti-amyloid treatment for Alzheimer’s disease. This new formulation allows for at-home administration, potentially reducing healthcare resource demands and streamlining treatment pathways, marking a significant advancement in Alzheimer’s care.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biotechnology company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company collaborates with Eisai to develop and commercialize the lecanemab antibody, targeting amyloid-beta in Alzheimer’s treatment, with a market focus on innovative drug formulations.
Average Trading Volume: 283,568
Technical Sentiment Signal: Buy
Current Market Cap: SEK27B
Learn more about BIOA.B stock on TipRanks’ Stock Analysis page.